8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 14, 2010

BSD MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-10783	75-1590407
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2188 West 2200 South

Salt Lake City, Utah 84119

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code:  (801) 972-5555

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On December 14, 2010, BSD Medical Corporation (the “Company”) issued a press release announcing success in the Company’s initial product launch for the MicroThermXMicrowave Ablation System (MTX-180).  BSD’s initial product launch has been focused on placement of a select number of systems with pivotal, high-profile, interventional oncology, key opinion leaders.  BSD has successfully placed three of these systems and will shortly place a fourth system.  A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated December 14, 2010

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BSD MEDICAL CORPORATION
Date:  December 14, 2010
	By:  /s/ Dennis P. Gauger
	Name:  Dennis P. Gauger
	Title:    Chief Financial Officer

-3-

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated December 14, 2010

-4-

EX-99.1

	Exhibit 99.1
Contact: Dennis Gauger
BSD MEDICAL CORPORATION	Telephone: (801) 972-5555
2188 West 2200 South	Facsimile: (801) 972-5930
Salt Lake City, Utah 84119-1326	Email: investor@bsdmc.com
	NASDAQ:BSDM

For Immediate Release

BSD Medical Announces Success in Initial Product Launch for MicroThermX Microwave Ablation System

SALT LAKE CITY, December 14, 2010—BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced success in the Company’s initial product launch for the MicroThermXMicrowave Ablation System (MTX-180).  BSD’s initial product launch has been focused on placement of a select number of systems with pivotal, high-profile, interventional oncology, key opinion leaders.  BSD has successfully placed three of these systems and will shortly place a fourth system.

The first two systems have been placed at clinical sites in Salt Lake City, Utah – St. Mark’s Hospital, part of MountainStar Healthcare, and the George E. Wahlen Department of Veterans Affairs Medical Center.  The third system has been placed at William Beaumont Hospital in Detroit, Michigan, and the fourth system is pending placement at Rhode Island Hospital.  BSD has received very positive feedback from the clinicians following liver treatments with the MTX-180.

Referring to his first patient treatment, James G. Carlisle, M.D. an interventional oncologist stated, “BSD has hit the ball out of the park. The MicroThermX Microwave Ablation System provides multiple benefits, including quick set-up time, ease of use, and a big reduction in footprint. Of course, the ablation zones are large and predictable.”

Dr. Carlisle has the most extensive experience in providing image-guided, minimally invasive cancer therapies in the Intermountain West. He treats patients at St. Mark’s Hospital and the George E. Wahlen Department of Veterans Affairs Medical Center.

About St. Mark’s Hospital and MountainStar Healthcare

Established as Utah’s first hospital in 1872, St. Mark’s Hospital brings nearly 140 years of experience to delivering patient care.  It is the only one in the state to achieve the HealthGrades Patient Safety Excellence Award in 2010, and to sustain a Distinguished Hospital Award for Clinical Excellence for three consecutive years.  St. Mark’s Hospital has been ranked as a 100 Top Hospital® for cardiovascular care eight-times, and as an overall 100 Top Hospital five-times by Thomson Reuters. www.stmarkshospital.com.

MountainStar Healthcare delivers nationally recognized patient care—when and where it’s needed.  It provides high-quality healthcare services and advanced technologies at six hospitals and the only satellite emergency department in Utah, as well as two hospitals in Idaho, one in Alaska, and a growing number of physician, surgery and imaging centers.  www.notbiggerjustbetterhealth.com.

	Exhibit 99.1
Contact: Dennis Gauger
BSD MEDICAL CORPORATION	Telephone: (801) 972-5555
2188 West 2200 South	Facsimile: (801) 972-5930
Salt Lake City, Utah 84119-1326	Email: investor@bsdmc.com
	NASDAQ:BSDM

About George E. Wahlen Department of Veterans Affairs Medical Center

The George E. Wahlen Department of Veterans Affairs Medical Center (VA), located in Salt Lake City is the major referral center for the Intermountain West veteran population. The VA provides complete and comprehensive care ranging from basic primary care to complex surgical procedures.

About the MicroThermXMicrowave Ablation System

The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system.  The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator.  The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure.  The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream.  The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MTX-180 for ablation of soft tissue. BSD has also received CE Marking for the MTX-180 System.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy.  BSD’s product lines include both hyperthermia and ablation treatment systems.  BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy.  BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue.  The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the Uni ted States, Europe and Asia.  Certain of the Company’s products have received regulatory approvals in the United States, Europe and China.  For further information visit BSD Medical's website at www.BSDMedical.com.

###

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.